Author

N. Iwanaga

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 2 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:host-pathogen & immune response· 2 Organism:mouse· 2 Research Focus:drug response / drug discovery· 1 Organism:human· 1 Assay:protein structure· 1

Frequent Co-Authors

B. Beddingfield· 2 shared J. Kolls· 2 shared A. Furumoto· 1 shared A. Watanabe· 1 shared C. J. Roy· 1 shared G. Bix· 1 shared H. Liu· 1 shared H. Mukae· 1 shared

Activity by Year

2020-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 18 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersMicrobiology

B. Beddingfield

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

MicrobiologybioRxivPreprintOct 6, 2023

Analysis of chronic host-aspergilloma interactions using a novel mouse model

R. Hamashima, M. Tashiro, Y. Nakano…·K. Izumikawa

This paper develops a novel mouse model of aspergilloma to study host-fungal interactions, revealing Th1/Th17 responses and angiogenesis induced by dead fungal hyphae.

DOI 10.1101/2023.10.06.561242

mouseexperimental assay

𝕏 PostBluesky

MicrobiologybioRxivJun 15, 2020

The Integrin Binding Peptide, ATN-161, as a Novel Therapy for SARS-CoV-2 Infection

B. Beddingfield, N. Iwanaga, P. P. Chapagain…·G. Bix

This paper explores ATN-161 as a potential therapy for SARS-CoV-2 by targeting the interaction between the spike protein and 5β1 integrin, alongside ACE2.

DOI 10.1016/j.jacbts.2020.10.003

humanexperimental assay

𝕏 PostBluesky

ImmunologybioRxivPreprintJun 15, 2020

Novel ACE2-IgG1 fusions with improved in vitro and in vivo activity against SARS-CoV2

N. Iwanaga, L. Cooper, L. Rong…·J. Kolls

This paper develops a modified ACE2-IgG1 fusion protein with enhanced in vivo activity against SARS-CoV2, showing improved lung bioavailability and viral neutralization.

DOI 10.1101/2020.06.15.152157

mouseprotein structure

𝕏 PostBluesky